• Thurs news: Sage R&D layoffs. Another Sanofi radiopharma deal. Novartis loses bid to block generic. Kezar lupus trial stopped. Why are so many pharmacies closing. See more on our front page

Valeant Keeps full year earnings guidance unchanged

Valeant posted a quarterly profit helped by the strong performance of its Bausch and Lomb Business.
Net income attributable to Valeant rose to $1.30Bil, or $3.69 per share, during the quarter , compared with a loss of $1.22Bil, or $3.49 per share, a year earlier.

Total revenue fell 10.5% to $2.22Bil, reflecting volume declines in its US diversified products and branded businesses.

Take a look at the earnings highlights including the guidance http://alph.st/b07a566e